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Background: Few studies have examined the association between use of aspirin or other non-steroidal anti-inflammatory drugs
(NSAIDs) and risk of glioma and the results have been equivocal. We therefore investigated the influence of NSAID use on glioma
risk in a nationwide setting.
Methods: We used national registries in Denmark to identify all patients aged 20–85 years with a first diagnosis of histologically
verified glioma during 2000–2009. Each case was matched on birth year and sex to eight population controls using risk-set
sampling. We used prescription data to assess NSAID use and classified exposure to low-dose aspirin or non-aspirin (NA) NSAIDs
into ever use or long-term use, defined as continuous use forX5 years. Conditional logistic regression was used to compute odds
ratios (ORs), with 95% confidence intervals (CIs), for glioma associated with NSAID use, adjusted for potential confounders.
Results: A total of 2688 glioma cases and 18 848 population controls were included in the study. Ever use of low-dose aspirin
(OR¼ 0.90; 95% CI: 0.77–1.04) or NA-NSAIDs (OR¼ 1.05; 95% CI: 0.96–1.14) was not associated with glioma risk. Compared with
never use, long-term use of low-dose aspirin or of NA-NSAIDs was associated with ORs of 0.80 (95% CI: 0.53–1.21) and 1.11 (0.57–
2.17), respectively. We observed no clear patterns of risk in stratified analysis according to estimated doses of low-dose aspirin
(p100mg, 150mg).
Conclusion: We did not find any apparent association between aspirin or NA-NSAID use and risk of glioma, although our results
may be consistent with a slight reduction in glioma risk with long-term use of low-dose aspirin.
Glioma is the most frequently diagnosed adult malignant primary
brain tumour in Denmark and other Nordic countries (Lo¨nn et al,
2004; Deltour et al, 2009). The most common histologic subtype of
glioma, glioblastoma multiforme, has a 5-year survival rate of only
3.3% (Bondy et al, 2008).
Exposure to ionising radiation is the only established environ-
mental cause of glioma (Fisher et al, 2007; Bondy et al, 2008).
However, laboratory studies of human glioma cell lines indicate that
the inducible enzyme cyclooxygenase (COX)-2 is overexpressed in
glioma tissue and that increasing levels of COX-2 are associated
with advanced tumour grade and poor survival (Joki et al, 2000;
Shono et al, 2001; Buccoliero et al, 2006; Perdiki et al, 2007).
Epidemiological studies of the effect of non-steroidal anti-
inflammatory drugs (NSAIDs) on the risk of brain tumours have
yielded conflicting results (Thun et al, 1993; Friis et al, 2003;
Sørensen et al, 2003; Ratnasinghe et al, 2004; Sivak-Sears et al,
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2004; Cook et al, 2005; Scheurer et al, 2008; Rothwell et al, 2011;
Daugherty et al, 2011; Ferris et al, 2012). Their inconsistent results
may be explained to a large extent by methodological limitations.
Assessment of long-term drug use is difficult in interview- or
questionnaire-based case–control studies, and this may be
particularly pertinent in patients with brain tumours, whose
cognitive skills may be impaired by the growth of the tumour
(Tucha et al, 2000; Teixidor et al, 2007). Moreover, most of the
epidemiological studies lack sufficient statistical precision owing to
the rarity of brain tumours and the likely assumption that any
effect of NSAIDs varies by histological subtype of the brain
tumour. As only few studies have specifically focused on the
association between NSAID use and risk of glioma (Sivak-Sears
et al, 2004; Scheurer et al, 2008; Daugherty et al, 2011; Ferris et al,
2012), we decided to conduct a large nationwide population-based
case–control study to further investigate this association.
MATERIAL AND METHODS
The present study was designed as a nationwide case–control study
based on information from the following Danish registries: Danish
Cancer Registry (DCR) (Storm et al, 1997; Gjerstorff, 2011), Civil
Registration System (Pedersen, 2011), National Prescription
Registry (Kildemoes et al, 2011), Danish National Registry of
Patients (DNRP) (Lynge et al, 2011), and Danish education and
fertility registries within Statistics Denmark (Jensen and
Rasmussen, 2011). Unambiguous linkage between the registries
was achieved through use of the civil registration number assigned
to all Danish residents since 1968, at birth or upon immigration to
the country (Pedersen, 2011).
Case ascertainment. The DCR has recorded incident cases of
malignant neoplasias on a nationwide basis since 1943 and has
been shown to achieve almost complete ascertainment of cancer
cases (Storm et al, 1997; Gjerstorff, 2011). All histological stages of
central nervous system (CNS) tumours, including gliomas, are
registered in the DCR. Cancer diagnoses are recorded according to
the International Classification of Diseases, version 10 (ICD-10)
and the ICD for Oncology (ICD-O-3) for topography and
morphology codes.
Eligible cases were individuals aged 20–85 years with a first
diagnosis of cranial or spinal glioma in the DCR during the period
1 January 2000–31 December 2009 and no previous history of
cancer (including CNS tumours and excluding non-melanoma
skin cancer). The glioma diagnosis was established on the basis of
ICD-10 and histologically confirmed ICD-O-3 diagnoses (see
Appendix for codes). We further classified cases according to
glioma subtype, that is, glioblastoma multiforme, astrocytoma
grades II and III, oligodendroglioma grades II and III, and ‘other’
(see Appendix Table 1). The diagnosis date recorded in the DCR
was defined as the index date.
Selection of population controls. For each case, eight controls
matched on birth year and sex were selected from the total Danish
population using the Civil Registration System (Pedersen, 2011)
and risk-set sampling (Rothman et al, 2008). The controls had to
be alive and at risk for a first diagnosis of cancer (including all CNS
tumours and excluding non-melanoma skin cancer) at the time the
corresponding case was diagnosed (i.e., index date for both cases
and controls). The Civil Registration System was used to restrict
cases and controls to persons who had resided in Denmark for at
least 10 consecutive years prior to the index date. As this restriction
was imposed after the sampling of controls, the final ratio of cases
to controls deviated slightly from 1:8.
Assessment of NSAIDs use. Information on use of NSAIDs
and other drugs was obtained from the National Prescription
Registry, which contains information on all prescriptions dis-
pensed at community pharmacies in Denmark since 1995
(Kildemoes et al, 2011). For each prescription, the Prescription
Registry records the dispensing date and a full description of
the dispensed product, including the anatomical therapeutic code
(ATC) (WHO, 2010), size and number of dosage forms
(e.g., tablets), and the total number of defined daily doses
(DDD). The DDD represents the typical daily dose required by
an adult when the drug is used for its main indication (WHO,
2010). Drugs used for the same indication are in principle
equipotent when measured in DDD.
We retrieved all information available from the Prescription
Registry from 1995 to the index date for both cases and controls.
We disregarded drugs dispensed within one year prior to the index
date to exclude potential drug use related to brain tumour
symptoms, in order to minimise the potential for reverse causation
bias (Csizmadl et al, 2007). Thus, first time use of any drug,
including NSAIDs, in the year prior to the index date was classified
as never use. Based on prescriptions of low-dose aspirin (ASA) or
non-aspirin NSAIDs (NA-NSAIDs) (ATC codes presented in
Appendix) dispensed during the period from 1995 up to 1 year
prior to the index date, study subjects were classified as ever users
(X1 prescription) or never users (no prescriptions) of low-dose
ASA or NA-NSAIDs. We classified ever use of low-dose ASA or
NA-NSAIDs into recent use (latest prescription redeemed 1–2.99
years prior to index date) and past use (latest prescriptions three or
more years prior to index date). We further defined continuous use
of low-dose ASA or NA-NSAIDs, computed as consecutive
treatment episodes defined by the dates of prescription and
number of days covered by the individual prescriptions. The
coverage of each prescription was calculated as the sum of DDDs
(for low-dose ASA: number of pills dispensed) for the prescription
plus a grace-period of 90 days. The grace-period was introduced to
allow some degree of non-compliance. A continuous treatment
period lasted for as long as consecutive prescriptions were
presented within the time-window defined by the coverage
(DDDþ grace-period) of the preceding prescription. According
to the timing of the most recent treatment episode in relation to
index date, that is, recent or past use, the duration of continuous
use was categorised into four mutually exclusive strata: o1, 1–2,
3–4, and X5 years.
For low-dose ASA, we calculated an estimated daily dose
defined as the most frequently prescribed tablet size during the
exposure period. This was categorised as a ‘low’ (p100mg) or
‘high’ (150mg) daily dose of low-dose ASA, assuming that the
vast majority of low-dose ASA users took one tablet daily. For
NA-NSAIDs, we assumed that most patients receiving long-term
therapy had a daily use corresponding to the DDD for the
individual drugs. Therefore, we did not estimate daily doses of
NA-NSAIDs.
Finally, we performed separate analyses for the two most
frequently prescribed NA-NSAIDs in Denmark, that is, ibuprofen
and diclofenac.
Potential confounders. Patients suffering from stroke are
frequently prescribed low-dose ASA and typically undergo
neuroimaging, which in some instances reveals concomitant
gliomas. We thus included information on history of stroke
obtained from the DNRP (see ICD codes in Appendix), which
contains inpatient data (from 1977 onwards) and outpatient data
(from 1995 onwards) for all non-psychiatric hospitals in Denmark,
including dates of admission/contact and diagnosis codes.
A recent meta-analysis of 12 observational studies reported an
inverse association between allergy (asthma, eczema, and hay
fever) and risk of glioma (Chen et al, 2011). A history of allergy or
asthma recorded in the DNRP was therefore included as a potential
confounder (see ICD codes in Appendix Table 1).
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As diabetes is under intense scrutiny for its possible association
with cancer risk (Carstensen et al, 2012), and is potentially
associated with ASA use, we classified study subjects as diabetics if
they had a history of diabetes mellitus according to the DNRP
(Lynge et al, 2011) or had redeemed prescriptions for antidiabetic
drugs prior to the index date (see ATC codes in the Appendix). We
also considered certain other drugs as potential confounders,
including postmenopausal hormone replacement therapy (HRT),
statins, antihistamines, and anti-asthma medications (ATC codes
in Appendix). Study subjects were classified according to use (X1
prescription one or more years prior to the index date) or no use
(no prescriptions) of these drugs.
We used parity as a proxy measure for exposure to endogenous
sex hormones in women, as female sex hormones may influence
glioma risk (Fisher et al, 2007). Parity was assessed for female cases
and controls based on information in the nationwide Fertility
Database (Blenstrup and Knudsen 2011). Female study subjects
were classified into the following categories according to number of
live births: 0 (nullipara), 1, 2, 3þ , or ‘missing information’.
As a marker of socioeconomic status, we included information
on highest educational level achieved by study subjects according
to annually updated information from registries at Statistics
Denmark (Jensen and Rasmussen 2011). We divided study subjects
into three categories according to number of years of schooling
(7–10, 11–12, and 13þ years).
Statistical analysis. Cases and controls were matched on age
(birth year), sex, and year of index date. We used conditional
logistic regression to compute adjusted odds ratios (and 95% CIs)
for glioma associated with low-dose ASA or NA-NSAID use,
adjusting for years of schooling, history of diabetes, stroke, allergy
or asthma, and use of statins, antihistamines or anti-asthma
medication. We also performed analyses restricting cases to
glioblastoma multiforme. Information on HRT use and parity
was included only in sensitivity analyses restricted to female study
subjects. Finally, we examined the presence of potential effect
measure modification of age, by stratifying analyses according to
the median age of the study subjects. All analyses were performed
using Stata SE 12.1 (StataCorp, College Station, TX, USA). The
study was approved by the Danish Data Protection Agency and the
Danish Medicines Agency.
RESULTS
Our study population consisted of 2688 cases and 18 848 controls.
Of these, 1606 cases (59.8%) and 11 656 controls (61.8%) were
male. Cases and controls were also similar with regard to the
distribution of age, parity, years of schooling, prevalence of
diabetes, stroke, allergy, asthma, and use of NSAIDs, statins, anti-
asthmatics and antihistamines, and HRT (Table 1).
Ever use of low-dose ASA (OR¼ 0.90; 95% CI: 0.77–1.04) or
NA-NSAIDs (OR¼ 1.05; 95% CI: 0.96–1.14) were not associated
with risk of glioma. These risk estimates were not markedly
influenced by recency of drug use (Table 2), and similar risk
estimates were also found for recent long-term use (X5 years) of
low-dose ASA and NA-NSAIDs (Table 3). Classification of
duration of use as continuous had limited influence on the results
(Table 3). The risk of glioma associated with ever use of low-dose
ASA was slightly lower for estimated daily doses of 150mg
(OR¼ 0.82; 95% CI: 0.67–1.01) compared with p100mg
(OR¼ 0.90; CI: 0.75–1.09) ASA (Table 4). Risk estimates for ever
use of ibuprofen or diclofenac were similar to those for total use of
NA-NSAIDs (data not presented).
In analyses restricted to cases of glioblastoma multiforme
(n¼ 1561) and their matched controls, long-term continuous use
of low-dose ASA or NA-NSAIDs were associated with ORs of 0.88
(95% CI: 0.54–1.42) and 1.56 (95% CI: 0.71–3.46), respectively.
There were too few data on other types of gliomas to allow a formal
analysis of their association with ASA or NA-NSAID use.
For both ASA and NA-NSAID, we observed no apparent risk
variation according to age (o and X58 years; data not shown).
Finally, we performed a number of sensitivity analyses. First, we
repeated all analyses after (1) redefining the ‘non-use’ reference
group to more than two prescriptions, (2) introducing a lag-time of
2 years prior to the index date, (3) introducing varying length of
the grace periods (60 or 120 days) used to compute treatment
episodes, and (4) using cumulative use of NSAID (total treatment
period during the exposure period regardless of whether the
treatment was continuous or not) instead of continuous use.
Table 1. Characteristics of study subjects in a nationwide case–control
study of glioma in Denmark, 2000–2009
Characteristic
Cases
(N¼2688)
Controls
(N¼18848)
Gender
Female 1082 (40.3) 7192 (38.2)
Male 1606 (59.8) 11 656 (61.8)
Age (years)
20–29 119 (4.4) 789 (4.2)
30–39 215 (8.0) 1487 (7.9)
40–49 422 (15.7) 3033 (16.1)
50–59 692 (25.7) 5019 (26.6)
60–69 742 (27.6) 5231 (27.8)
70–79 434 (16.2) 2896 (15.4)
80–85 64 (2.4) 393 (2.1)
Parity, number of childrena,b
0 97 (9.0) 658 (9.2)
1 167 (15.4) 1122 (15.6)
2 419 (38.7) 2739 (38.1)
3þ 241 (22.3) 1668 (23.2)
Missing 158 (14.6) 1005 (14.0)
Schooling, number of years
7–10 951 (35.4) 6535 (34.7)
11–12 1100 (40.9) 7754 (41.1)
13þ 594 (22.1) 4196 (22.3)
Missing 43 (1.6) 363 (1.9)
Morbidity
Diabetes 94 (3.5) 820 (4.4)
Stroke 72 (2.7) 430 (2.3)
Allergy 67 (2.5) 512 (2.7)
Drug use
Aspirin, low-dose 320 (11.9) 2405 (12.8)
Non-aspirin NSAIDsc 1588 (59.1) 10 945 (58.1)
Selective cox2-inhibitors 160 (6.0) 963 (5.1)
Statins 214 (8.0) 1644 (8.7)
Anti-asthma drugs 307 (11.4) 2311 (12.3)
Antihistamines 237 (8.8) 1705 (9.1)
Postmenopausal hormone
replacement therapya
295 (27.3) 2130 (29.6)
Abbreviation: NSAIDs¼ nonsteroidal anti-inflammatory drugs. Numbers are expressed in
percentages.
aWomen only.
bData incomplete for women born before 1945. No data available on births in 2009.
cNon-steroidal anti-inflammatory drugs including Cox2-inhibitors.
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Furthermore, for NA-NSAIDs, we also calculated intensity of use,
that is, total number of DDD divided by time period between first
and last prescription, and classified this into tertiles. Subsequently,
we performed analyses comparing glioma risk associated with
long-term, high-intensity use (upper tertile) with never use of NA-
NSAIDs. Finally, analyses with women in separate strata were
repeated with HRT and parity included as confounder variables.
The results of all sensitivity analyses were similar to those of the
main analyses (data not presented).
DISCUSSION
We found that long-term use of NA-NSAIDs was not associated
with reduced risk of glioma. However, our findings may be
consistent with a small reduction in glioma risk associated with the
long-term use of low-dose ASA. These findings should be
interpreted cautiously due to limited statistical precision, notably
in the duration and dose-response analyses.
Some previous case–control studies, all based on self- or proxy-
reported data on drug use, have reported an inverse association
between use of NSAIDs and risk of glioma (Scheurer et al, 2008;
Ferris et al, 2012) or glioblastoma multiforme (Sivak-Sears et al,
2004). These results were not supported by a recent cohort study
(Daugherty et al, 2011), based on 341 incident cases of glioma
among 302 767 individuals, that reported null results for the
association between regular use of ASA or NA-NSAIDs and risk of
glioma. Other prospective studies lacked sufficient statistical
precision to evaluate brain tumours by histologic type. The
majority of these studies did not find a reduced risk of brain
tumours associated with ASA or NA-NSAID use (Thun et al, 1993;
Friis et al, 2003; Sørensen et al, 2003; Ratnasinghe et al, 2004;
Table 2. Ever use of nonsteroidal anti-inflammatory drugs and risk of
glioma
Cases Controls
Crude odds
ratio (95% CI)
Adjusted odds
ratioa (95% CI)
Aspirin, low-dose
Never 2368 16443 1 (reference) 1 (reference)
Ever 320 2405 0.89 (0.78–1.01) 0.90 (0.77–1.04)
Recentb 270 2003 0.91 (0.79–1.05) 0.91 (0.77–1.07)
Pastc 50 402 0.81 (0.59–1.09) 0.80 (0.59–1.09)
Non-aspirin NSAIDs
Never 1100 7903 1 (reference) 1 (reference)
Ever 1588 10945 1.04 (0.96–1.13) 1.05 (0.96–1.14)
Recentb 800 5408 1.04 (0.94–1.15) 1.06 (0.95–1.17)
Pastc 788 5537 1.04 (0.94–1.15) 1.05 (0.94–1.17)
Abbreviations: CI¼ confidence interval; NSAIDs¼ nonsteroidal anti-inflammatory drugs.
aAdjusted for education, diabetes, stroke, allergy, asthma, use of statins, antihistamines,
and anti-asthma medication.
bMost recent prescriptions 1–2.99 years prior to index date.
cMost recent prescriptions X3 years prior to index date.
Table 3. Duration of use of nonsteroidal anti-inflammatory drugs and risk of glioma
Aspirin, low-dose Non-aspirin NSAIDs
Cases Controls
Adjusted odds
ratioa (95% CI) Cases Controls
Adjusted odds
ratioa (95% CI)
Never use 2368 16443 1 (reference) 1100 7903 1 (reference)
Ever useb
Recent use, years
o2 171 1222 0.96 (0.79–1.16) 762 5107 1.06 (0.95–1.17)
2–4 68 529 0.80 (0.60–1.06) 24 188 0.97 (0.60–1.57)
X5 31 252 0.80 (0.53–1.21) 14 113 1.11 (0.57–2.17)
Past use, years
o2 47 363 0.84 (0.61–1.15) 784 5502 1.05 (0.95–1.17)
X2 3 39 0.47 (0.14–1.55) 4 35 0.91 (0.29–2.83)
Abbreviations: CI¼ confidence interval; NSAIDs¼ nonsteroidal anti-inflammatory drugs.
aAdjusted for education, diabetes, stroke, allergy, asthma, use of statins, antihistamines, and anti-asthma medication.
bLength of most recent treatment period with continuous prescribing, that is, gap of no more than 90 days between duration of consecutive prescriptions.
Table 4. Dose of aspirin and risk of glioma
Cases Controls
Adjusted odds
ratioa (95% CI)
Never use 2368 16443 1 (reference)
p100mgb
Ever use 180 1357 0.90 (0.75–1.09)
Recent, continuous 156 1178 0.90 (0.74–1.11)
o5 years 141 1061 0.90 (0.73–1.12)
X5 years 15 117 0.88 (0.50–1.56)
150mgb
Ever use 140 1048 0.82 (0.67–1.01)
Recent, continuous 114 825 0.85 (0.68–1.07)
o5 years 98 690 0.87 (0.69–1.11)
X5 years 16 135 0.74 (0.42–1.29)
Abbreviation: CI¼ confidence interval.
aAdjusted for education, diabetes, stroke, allergy, asthma, use of statins, antihistamines,
and anti-asthma medications.
bIn users of more than one dose of aspirin, the most frequently used dose was chosen.
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Cook et al, 2005). A notable exception is a recent post-trial analysis
of individuals who participated in randomized clinical trials of
ASA and cardiovascular disease (Rothwell et al, 2011). In that
study, a subanalysis for brain tumour, based on small numbers,
indicated that long-term use of low-dose ASA was associated with
a substantially reduced risk of death (hazard ratio¼ 0.31; 95% CI:
0.11–0.89) due to primary brain tumours during the first 10 years
following randomisation, but not thereafter (hazard
ratio¼ 1.16;95% CI: (0.49–2.77) (Rothwell et al, 2011). Our results
are more in line with the majority of other cohort studies,
including the only cohort study that specifically examined risk of
glioma associated with NSAID use (Daugherty et al, 2011). We
believe this may be due to our ascertainment of drug use through
registries. We thus eliminated recall bias, a potential methodolo-
gical shortcoming of previous case–control studies.
Our study has a number of other strengths. We used nationwide
registries with complete coverage and continuously collected data
on all Danish residents, an approach that minimised selection bias.
The DCR enabled us to identify incident cases of glioma and
cancer-free controls with minimal misclassification. We also
restricted our sample to histologically verified cases, which
enhanced case validity and allowed us to perform analyses on
subtypes of glioma.
A number of potential limitations should also be noted. Over-
the-counter use of NSAIDs is not recorded in the Prescription
Registry. However, in Denmark in 2009, 90% of low-dose ASA and
81% of NA-NSAIDs were purchased through prescriptions
(www.medstat.dk/en). Among NA-NSAIDs, only low-dose
(200mg) ibuprofen was available over-the-counter in Denmark
in the study period. We therefore believe that over-the-counter use
only resulted in minor misclassification of low-dose ASA and NA-
NSAID use. High-dose ASA is primarily sold over-the-counter in
Denmark and we could therefore not directly account for its use in
our study. However, in Denmark high-dose ASA is used primarily
for the relief of acute pains, that is, backaches, headaches, sports
injuries and so on, and is thus mainly used as short-term therapy
that most likely has limited, if any, biological effect on risk of
glioma.
Since the Prescription Registry was established in 1995, drug
histories only spanned 5–15 years, depending on index date. This
left-truncation of prescription data may induce two potential
problems. First, study subjects who stopped using NSAIDs prior to
1995 were misclassified as never users in our study. Second, the
duration of current use may be underestimated in subjects with
NSAID use prior to 1995. Such misclassifications would most likely
result in a conservative misclassification bias, that is, attenuation of
the association between NSAID use and glioma risk. Examining
NSAID prescription data from a regional registry (OPED) with
complete coverage of a Danish county (Funen) since 1990, we
found that the extent of misclassification due to left truncation of
NSAID use is probably minor in the present study (Hallas,
personal communication).
Lifestyle factors could also influence our findings if such factors
were both related to the likelihood of being prescribed NSAIDs and
the risk of glioma. We find this scenario unlikely, as risk of glioma
has not been convincingly linked to lifestyle factors (Bondy et al,
2008). Residual confounding by socioeconomic indicators might
also have influenced our results, as we only adjusted the analyses
for highest achieved level of schooling. A Danish study, however,
based on DCR data found no association between socioeconomic
status and incidence of CNS tumours (Schmidt et al, 2008).
Therefore, we believe that lifestyle factors and socioeconomic
status are not likely to have substantially affected our findings.
It is conceivable that, prior to detection, brain tumours could
exert an influence on adherence to medication use, for example, by
affecting cognitive skills. However, by disregarding NSAID use in
the year prior to the index date, we believe that we have minimised
the impact of such effects. This conclusion was reinforced by the
fact that neither increasing the lag-time to 2 years or restricting
analyses to cases of glioblastoma multiforme, a glioma subtype
with well-established rapid development, had significant influence
on our results.
In conclusion, we did not find any apparent association between
ASA or NA-NSAIDs use and glioma risk, although there was some
indication of a slightly reduced overall risk of glioma with long-
term use of low-dose ASA. Analyses of longer durations are
warranted to test whether the effect of low-dose ASA becomes
stronger or if NA-NSAIDs confer a reduced risk.
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APPENDIX
Table 1. List of ICD-10, ICD-O-3, and ATC codes
Cancer codes
Glioma
ICD-10
C71.0-C71.9, C72.0, D33.0-D33.4, D43.0-D43.4
ICD-0-3 morphology
94403—glioblastoma multiforme
94003, 94013, 94103, 94113—astrocytoma grade II and III
94503, 94513, 94603—oligodendroglioma grade II and III
93801,93803, 93813, 93823, 93831,93900–94001, 94121–94401,
94413–94501—‘other’
ATC codes
Aspirin—low-dose
B01AC06—acetylsalicylic acid (75mg, 100mg, or 150mg per tablet)
B01AC30—acetylsalicylic acid (50mg per tablet) in combination with
dihydropyridamol
Non-aspirin nonsteroidal anti-inflammatory drugs
M01A (including Cox2 inhibitors), excluding M01AX
Other drugs (covariates)
Aspirin—high-dose
N02BA01—acetylsalicylic acid (500mg per tablet)
N02BA51—acetylsalicylic acid (500mg per tablet) in combination
excluding psycholeptics
Antidiabetics
A10A—insulin
A10B—oral antidiabetics
Table 1. ( Continued )
Allergy and asthma
R06A—antihistamines
R03—anti-asthma drugs
Hormone replacement therapy
G03C, G03D, G03F, G03HB01
Statins
C10AA01—Simvastatin
C10AA02—Lovastatin
C10AA03—Pravastatin
C10AA04—Fluvastatin
C10AA05—Atorvastatin
C10AA06—Cerivastatin
C10AA07—Rosuvastatin
Hospital discharge codes
Diabetes
ICD-8: 249, 250
ICD-10: E10–E14
Stroke
ICD-8: 431, 433, 434
ICD-10: I60, I61, I63
Allergy and asthma
ICD-8: 493, 507, 708, 69200, 69202, 69210, 69212, 69220, 69222,
69230, 69232, 69260, 69262
ICD-10: J45, J46, J30, L50, L23
Abbreviations: ATC¼Anatomical, therapeutical, chemical; ICD¼ International classification
of diseases.
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